Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Neuropharmacology. 2017 Jan 13;116:371–386. doi: 10.1016/j.neuropharm.2017.01.010

Fig. 7.

Fig. 7

Chronic dosing with the selective partial ADRB1 agonist, xamoterol, attenuated AT8-ir in the retrosplenial cortex (RS) in 5XFAD transgenic mice. A) Atlas plate indicates the level at which images were selected for analyses [1]. Black box indicates image capture frame. Number below atlas plate indicates mm bregma; black scale bar, 1 mm. Photomicrographs (10X magnification) illustrate representative AT8-immunostaining in wildtype and 5XFAD vehicle- (VEH) and xamoterol-treated (XAM) mice, white scale bar, 50 μm. B) Quantitative immunohistochemistry revealed increases in AT8-ir (% area) in VEH-treated 5XFAD transgenic mice relative to VEH-treated wildtype littermates. These increases were attenuated in transgenic mice chronically dosed with XAM. Sample size, n=5 per group. *p < .05, **p < .01, Bonferroni’s test for multiple comparisons following one-way ANOVA.